n-3 Fatty acids block TNF-α-stimulated MCP-1 expression in rat mesangial cells

Am J Physiol Renal Physiol. 2011 May;300(5):F1142-51. doi: 10.1152/ajprenal.00064.2011. Epub 2011 Mar 2.

Abstract

Monocyte chemoattractant protein 1 (MCP-1) is a CC cytokine that fundamentally contributes to the pathogenesis of inflammatory renal disease. MCP-1 is highly expressed in cytokine-stimulated mesangial cells in vitro and following glomerular injury in vivo. Interventions to limit MCP-1 expression are commonly effective in assorted experimental models. Fish oil, an abundant source of n-3 fatty acids, has anti-inflammatory properties, the basis of which remains incompletely defined. We examined potential mechanisms whereby fish oil reduces MCP-1 expression and thereby suppresses inflammatory responses to tissue injury. Cultured mesangial cells were treated with TNF-α in the presence of the n-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA); equimolar concentrations of the n-6 fatty acids LA and OA served as controls. MCP-1 mRNA expression was assessed by Northern blotting, and transcriptional activity of the MCP-1 promoter was assessed by transient transfection. The involvement of the ERK and NF-κB pathways was evaluated through transfection analysis and the use of the MEK inhibitor U0126. DHA and EPA decreased TNF-α-stimulated MCP-1 mRNA expression by decreasing transcription of the MCP-1 gene. DHA and EPA decreased p-ERK expression and nuclear translocation of NF-κB, both of which are necessary for TNF-α-stimulated MCP-1 expression. Both NF-κB and AP-1 sites were involved in transcriptional regulation of the MCP-1 gene by DHA and EPA. We conclude that DHA and EPA inhibit TNF-α-stimulated transcription of the MCP-1 gene through interaction of signaling pathways involving ERK and NF-κB. We speculate that such effects may contribute to the salutary effect of fish oil in renal and vascular disease.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Binding Sites
  • Cells, Cultured
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism*
  • Docosahexaenoic Acids / pharmacology*
  • Down-Regulation
  • Eicosapentaenoic Acid / pharmacology*
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Genes, Reporter
  • Humans
  • Male
  • Mesangial Cells / drug effects*
  • Mesangial Cells / immunology
  • Mesangial Cells / metabolism
  • NF-kappa B / metabolism
  • Promoter Regions, Genetic / drug effects
  • Protein Kinase Inhibitors / pharmacology
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins / metabolism
  • Transcription Factor AP-1 / metabolism
  • Transcriptional Activation / drug effects
  • Transfection
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Anti-Inflammatory Agents
  • Ccl2 protein, rat
  • Chemokine CCL2
  • NF-kappa B
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • Recombinant Proteins
  • Transcription Factor AP-1
  • Tumor Necrosis Factor-alpha
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid
  • Extracellular Signal-Regulated MAP Kinases